drugset / Trial / NCT02766777

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

NCT02766777

Phase 3 Completed 87 enrolled Sucampo Pharma Americas, LLC Sucampo AG · collab
NaSingle-groupOpen-labelTreatment

Summary

A study of the safety of lubiprostone in pediatric participants aged ≥ 6 Years to \< 18 years diagnosed with functional constipation.

Timeline

Start
2016-04-12
Primary completion
2016-11-04
Completion
2016-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 12 ug Oral
Subject Lubiprostone Small molecule 24 ug Oral

Indications